Unregistered Sales of Equity Securities and Use of Proceeds
−Removed: On May 29, 2024, we announced that our Board had authorized the repurchase of up to an additional $200.0 million aggregate purchase price (excluding any fees, commissions, or other expenses of such purchases) of Cimpress' issued and outstanding ordinary shares on the open market, through privately negotiated transactions, or in one or more self tender offers.
−Removed: The Board did not set an expiration date for this repurchase program, and we may suspend or discontinue our share repurchases at any time.
−Removed: The following table outlines the repurchase of our ordinary shares during the three months ended December 31, 2025 under the program described above:
+Added: On March 25, 2026, our Board authorized the repurchase, from time to time, with no expiration date, of up to $200.0 million aggregate purchase price (excluding any fees, commissions, or other expenses of such purchases) of Cimpress' issued and outstanding ordinary shares on the open market, through privately negotiated transactions, or in one or more self-tender offers.
+Added: This authorization replaced the remaining unused portion of the $200.0 million share repurchase authorization previously approved by our Board on May 29, 2024, which was terminated immediately prior to the effectiveness of the new authorization.
+Added: The Board’s authorization does not necessarily mean that we will repurchase the full dollar amount authorized.
+Added: Share repurchases remain subject to Cimpress’ net leverage and capital allocation priorities and may be suspended or discontinued at any time.
+Added: The following table outlines the repurchase of our ordinary shares during the three months ended March 31, 2026, under the program described above:
Total Number of Shares Purchased Average Price Paid Per Share Total Number of Shares Purchased as Part of a Publicly Announced Program Approximate Dollar Value of Shares that May Yet be Purchased Under the Program
(in millions)
−Removed: October 1, 2025 through October 31, 2025 — $ — — $ 112.6
−Removed: November 1, 2025 through November 30, 2025 239,711 66.71 239,711 96.6
−Removed: December 1, 2025 through December 31, 2025 130,000 72.83 130,000 87.1
+Added: January 1, 2026 through January 31, 2026 168,365 $ 76.13 168,365 $ 74.3
+Added: February 1, 2026 through February 28, 2026 119,744 75.77 119,744 65.2
+Added: March 1, 2026 through March 31, 2026 — — — 200.0
Total 288,109 $ 75.98 288,109 $ 200.0
−Removed: Exhibits and Financial Statement Schedules
−Removed: 31.1 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Rule 13a-14(a)/15d-14(a), by Chief Executive Officer
−Removed: 31.2 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Rule 13a-14(a)/15d-14(a), by Chief Financial Officer
−Removed: 32.1 Certification pursuant to 18 U.S.C.
−Removed: Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by Chief Executive Officer and Chief Financial Officer
−Removed: __________________
−Removed: *Management contract or compensatory plan or arrangement
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: January 29, 2026 Cimpress plc
−Removed: Chief Financial Officer
−Removed: (Principal Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.